OrganoClick: Weaker Q4 likely, but set up for a stronger H1 - ABG

Q4e sales of SEK 23.9m, down 14% y-o-y, EBIT SEK -7m (-6m)
NW&FT and FW weak while momentum continues in GC&MP
Hopeful of a recovery in '25e, lower interest rates to drive NW&FT


Q4 expectations

In the company's seasonally weakest quarter, Q4, we expect sales of SEK 23.9m, down 14% y-o-y, as the NW&FT and FW segments continue to face headwinds from weak end-markets, while GC&MP continues its strong performance thanks to good product momentum with new customer launches during the year. On EBIT, we have SEK -7m (-6m), down only slightly y-o-y due to lower sales but improved cost control.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/organoclick/Equity-research/2025/1/organoclick---weaker-q4-likely-but-set-up-for-a-stronger-h1/